Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Kenneth J. Bloom, MD
Advertisement
Articles by Kenneth J. Bloom, MD
Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays
Advertisement
Latest Updated Articles
Dr. Bloom Compares HER2 Screening AssaysJanuary 30th 2012
Dr. Bloom Explains Situations Requiring HER2 RetestingFebruary 16th 2012
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5